Provided are iridium complexes having a ligand L.sub.A of Formula I

##STR00001##

Also provided are formulations comprising these iridium complexes. Further provided are OLEDs and related consumer products that utilize these iridium complexes.

The inventive subject matter provides compounds, compositions and methods for lowering serum acid (sUA) for the treatment of gout, and having reduced liver toxicity, associated with CYP2C9 metabolic pathway.

A compound may improve the capability of an organic EL device, and an organic electroluminescent device including such compound may have improved capability and may be included in electronic devices. Such compounds may be of formula (1A) or formula (1B) (wherein the symbols are as defined in the description)

##STR00001##

organic electroluminescent device(s) may contain such compound(s), and electronic device(s) may include such organic electroluminescent device(s).

Tetrahydrocannabinol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##

Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogenic, androgenic, and estrogenic activity, which can prevent or inhibit bone density loss in subjects. Oligomeric compound embodiments disclosed herein provide the ability to control receptor activation and/or treatment by incorporating a tunable linker group which couples steroidal-based compounds to one another or with therapeutic agents and facilitates selective cleavage of the monomeric components of the oligomeric compound.

A pyrimidine compound as an AXL inhibitor is provided. The structure of the pyrimidine compound is as shown in general formula I, and the definition of each substituent is as described in the description. The present invention further provides a preparation method for the pyrimidine compound. The pyrimidine compound of the present invention has significant AXL inhibitory activity, and can be used as an AXL inhibitor.

##STR00001##

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

##STR00001##

A light emitting element of an embodiment includes a first electrode, a second electrode, and at least one functional layer disposed between the first electrode and the second electrode and including an amine compound represented by Formula 1 below, thereby showing high efficiency and long-life characteristics.

##STR00001##

Provided herein are compounds of Formula (I), (II), or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), (II), or a pharmaceutically acceptable salt thereof.

##STR00001##

A light emitting device that includes a first electrode, a second electrode oppositely disposed to the first electrode, and an emission layer between the first electrode and the second electrode is provided. The emission layer includes an organometallic compound represented by Formula 1:

##STR00001##